Rare Discussions

Rare Discussions

By CheckRare EditorsMedicineHealth & Fitness
Download on the App Store

Rare Discussions episodes

  • International Rett Syndrome Foundation Works to Advance Research and Support Families
    Laura Hameed, Chief Executive Officer, and Dominique Pichard, MD, MS, Chief Scientific and Medical Officer of the International Rett Syndrome Foundation (IRSF), discuss the changing treatment landscape for Rett syndrome and the organization’s commitment to supporting patients and their families.

    Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.

    Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.

    Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.

    Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.


    39 min
  • Three-Year Study Finds Burosumab Improves Symptoms in Adults With X-Linked Hypophosphatemia
    Steven Ing, MD, Professor of Clinical Medicine in the Division of Endocrinology, Diabetes and Metabolism at The Ohio State University Wexner Medical Center, discusses three-year real-world findings from an interim analysis of the XLH Disease Monitoring Program (DMP) comparing burosumab with conventional therapy in adults with X-linked hypophosphatemia (XLH).

    Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.

    Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.

    Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.

    Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.


    9 min
  • Trutakna Meets All Prespecified Endpoints in Phase 3 ORIGIN 3 Trial in IgA Nephropathy
    Positive final efficacy results from the phase 3 ORIGIN 3 trial, evaluating Trutakna (atacicept) in adults with primary IgA nephropathy (IgAN) at risk of disease progression. Marshall Fordyce, MD, founder and CEO of Vera Therapeutics, discusses the findings

    Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.

    Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.

    Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.

    Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.


    14 min
  • Analysis Finds Ralinepag Reduces Clinical Worsening Across PAH Risk Profiles
    A poster analysis of the phase 3 ADVANCE OUTCOMES trial, presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona, found that oral ralinepag reduced clinical worsening across different baseline risk profiles in patients with pulmonary arterial hypertension (PAH).

    Jean Elwing, MD, FCCP, Professor of Clinical Internal Medicine at the University of Cincinnati, discusses the findings and their implications for PAH treatment. 

    Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.

    Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.

    Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.

    Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.


    8 min
  • The Need for Earlier Pulmonary Hypertension Screening in Interstitial Lung Disease
    Parth Rali, MD, MBBS, FCCP, pulmonologist at Temple Health, discusses interim findings from the PHINDER study evaluating pulmonary hypertension (PH) screening strategies in patients with interstitial lung disease (ILD).

    Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.

    Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.

    Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.

    Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.


    12 min
  • UCB Study Highlights the Burden of Ocular Myasthenia Gravis
    Biopharmaceutical company UCB recently shared findings from a mixed-methods study examining the experiences and unmet needs of people living with ocular myasthenia gravis (oMG). The findings were presented at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session.

    Anna Kole, Global Patient Engagement Lead for Myasthenia Gravis at UCB, discusses the findings and explains how patient perspectives could improve clinical research and care.

    Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.

    Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.

    Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.

    Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.


    12 min
  • Inhaled Treprostinil Reduces Multiple Disease Progression Events in IPF
    A post-hoc analysis of the phase 3 TETON-2 study, presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona, found that inhaled treprostinil significantly reduced multiple disease progression events in patients with idiopathic pulmonary fibrosis (IPF).

    Steven Nathan, MD, MBBCh, FCCP, Director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital, discusses the findings and their implications for patients. 

    Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.

    Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.

    Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.

    Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.


    10 min
  • Phase 3 OASIS Study Shows Promise of Oral Olorofim for Invasive Aspergillosis
    Johan Maertens, MD, PhD, Professor of Hematology at University Hospitals Leuven (UZ Leuven) in Belgium and Principal Investigator of the OASIS study, discusses positive phase 3 trial results evaluating oral olorofim in patients with invasive aspergillosis.

    Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.

    Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.

    Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.

    Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.


    8 min
  • Garetosmab Demonstrates Sustained Efficacy in Adults With Fibrodysplasia Ossificans Progressiva
    Richard Keen, MD, PhD, Director of the Metabolic Bone Disease Centre at the Royal National Orthopaedic Hospital in London and global principal investigator of the OPTIMA trial, discusses positive 84-week results from the phase 3 OPTIMA trial extension, evaluating Pasatru (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP).

    Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.

    Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.

    Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.

    Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.


    6 min
  • C3G and the Pediatric VALIANT Study
    Bradley Dixon, MD, a pediatric nephrologist, and Chief of Pediatric Nephrology, Children’s Hospital of Colorado, and Professor of Pediatrics, University of Colorado School of Medicine, discussed complement 3 glomerulopathy (C3G) with CheckRare.

    Complement 3 glomerulopathy (or C3G) is a form of membranoproliferative glomerulonephritis, an inflammatory process. It occurs when the complement system, which is a key part of the body’s defenses to fight off bacterial and viral infection, is continually engaged. When this occurs, plasma complement fragments are deposited in the glomerulus, creating inflammation and disrupting glomerular function. At this point, the clinical features of C3G are apparent, including hematuria and proteinuria.

    As it is a rare disorder, it is not regularly taught during medical training, and primary care physicians will not typically see several patients with C3G. Therefore, it will not often be in the forefront of clinician’s mind when confronted with symptoms associated with C3G. Primarily a disease of the young, pediatricians may easily mistake it for other conditions, such as postinfectious (or infection-related) glomerulonephritis, which typically follows a streptococcal infection. The microscopic appearance of biopsy samples from patients with C3G may even look similar to those with postinfectious glomerulonephritis.

    The VALIANT trial was a phase 3, double-blind, placebo-controlled study of the efficacy and safety of pegcetacoplan in 124 adolescent and adult patients with either C3G or the related disorder primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). The primary endpoint was to determine this complement 3 inhibitor’s effect on proteinuria.

    After 26 weeks of treatment, pegcetacoplan was associated with a 68% relative reduction in the urinary protein:creatinine ratio, the indicator of proteinuria, compared with the individuals receiving placebo. The study drug was not associated with a safety profile that was significantly different from that observed in the placebo group. A longer-term extension study demonstrated that the proteinuria reduction is maintained, along with kidney function, through at least 52 weeks. “Improvement in proteinuria really does herald long-term benefit,” stated Dr. Dixon. “The longer we see preservation of GFR, the more confident we are that these drugs will be effective over the long term.”

    The VALIANT data support that blocking C3 has dramatic benefits by limiting complement deposition in the glomerulus in both adolescent and adults with C3G. With earlier intervention, long-term damage to kidney function may be prevented.

    Dr. Dixon commented that although pegcetacoplan was effective in patients ages 12 years or greater, there is still an urgent need for treatment of younger patients, for which no effective treatment is approved. He added that since we are all born with a fixed number of glomeruli, kidney damage in young patients means their reserve of kidney function later in life will be limited. In his experience, 50% of patients with C3G will experience a halving of their kidney function within 10 years, and will need dialysis and/or a kidney transplant.

    Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.

    Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.

    Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.

    Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.


    11 min

About Rare Discussions

From the publisher's feed

Conversations with the leaders advancing rare disease care.  

Rare Discussions is CheckRare's flagship interview podcast featuring conversations with leading physicians, researchers,…